Evaluation of a Novel Array-Based Toxoplasma, Rubella, Cytomegalovirus, and Herpes Simplex Virus IgG Enzyme Linked Immunosorbent Assay and Its Comparison with Virion/Serion Enzyme...

por Wu, Dongsheng, Wu, Yuanjian, Wang, Liuhong, Xu, Weidong, Zhong, Qiao
Publicado 2014

High fever and multi-nodular lung consolidations after whole lung lavage in a patient with pulmonary alveolar proteinosis

por Zhang, Shufang, Wang, Yesong, Xu, Zhihao, Ding, Liren, Wang, Liuhong, Li, Libin, Zhang, Gensheng
Publicado 2015

Accuracy of Magnetic Resonance Imaging in Staging Rectal Cancer with Multidisciplinary Team: A Single-Center Experience

por Yu, Linzhen, Wang, Liuhong, Tan, Yinuo, Hu, Hanguang, Shen, Li, Zheng, Shu, Ding, Kefeng, Zhang, Suzhan, Yuan, Ying
Publicado 2019

The paradigm of tumor shrinkage and rapid liver remnant hypertrophy for conversion of initially unresectable colorectal liver metastasis: a case report and literature review

por Xiao, Nan, Yu, Kailin, Yu, Shaojun, Wu, Jianjun, Wang, Jian, Shan, Siyang, Zheng, Shuchun, Wang, Liuhong, Wang, Jianwei, Peng, Shuyou
Publicado 2017

Phase II study of anlotinib in combination with oxaliplatin and capecitabine for patients with RAS/BRAF wild-type metastatic colorectal adenocarcinoma as the first-line therapy

por Liu, Yue, Xiao, Qian, He, Jinjie, Hu, Hanguang, Du, Jinlin, Zhu, Yuping, Chen, Jiaqi, Liu, Zhuo, Wang, Jianping, Sun, Lifeng, Xu, Dong, Li, Jun, Liao, Xiujun, Wang, Jianwei, Cai, Yibo, Cai, Cheng, Jin, Zhekang, Wang, Liuhong, Yuan, Ying, Ding, Kefeng
Publicado 2022

Sintilimab plus bevacizumab, oxaliplatin and capecitabine as first-line therapy in RAS-mutant, microsatellite stable, unresectable metastatic colorectal cancer: an open-label, sing...

por Fang, Xuefeng, Zhu, Ning, Zhong, Chenhan, Wang, Liuhong, Li, Jun, Weng, Shanshan, Hu, Hanguang, Dong, Caixia, Li, Dan, Song, Yongmao, Xu, Dong, Wang, Jianwei, Sun, Lifeng, Wang, Jian, Wang, Zhanhuai, Cao, Hongfeng, Liao, Xiujun, Yu, Ningjuan, Xiao, Qian, Mi, Mi, Zhang, Suzhan, Ding, Kefeng, Yuan, Ying
Publicado 2023